Patients with metastic lung cancer have multiple treatment options. Selecting the right treatment requires comprehensive genomic test results.
Guardant360 has been extensively validated, please see our 80+ publications to learn more.
Lung tissue samples often run out before answering all the clinical questions that guide treatment selection. After the initial diagnosis, additional stains, and immuno-oncology markers, you still need status for EGFR, ALK, ROS1, BRAF, and more.
With Guardant360, you can get comprehensive genomic results from a simple blood draw.
Guardant360 fits into your practice,
delivering results in 7 days.
When molecular testing is incomplete, unobtainable, or limited.
For instance, when a patient is EGFR and ALK negative but lacks sufficient tissue for ROS1 or BRAF testing
To avoid an invasive biopsy when looking for a new genomic target.
To identify potential clinical trials or off-label therapies for patients who have exhausted their standard of care therapy options